[18F]FDG-PET/CT bei Lymphomen – Pitfalls und Normvarianten

Gregor Schweighofer-Zwink; Julia Pilz; Mohsen Beheshti; Christian Pirich

doi:10.1055/a-1668-4400

Angewandte Nuklearmedizin, Table of Contents

Angewandte Nuklearmedizin 2022; 45(01): 56-74
DOI: 10.1055/a-1668-4400

CME-Fortbildung

[¹⁸F]FDG-PET/CT bei Lymphomen – Pitfalls und Normvarianten

[¹⁸F]FDG-PET/CT in lymphoma – pitfalls and normal variants

Gregor Schweighofer-Zwink

,

Julia Pilz

,

Mohsen Beheshti

,

Christian Pirich

Abstract

Nuklearmediziner*innen sollten mit Normvarianten in der Bildgebung und häufigen Pitfalls, die zu Fehlinterpretationen und damit zu potenziellen Änderungen des Managements bei Patienten mit Hodgkin und Non-Hodgkin-Lymphomen führen könnten, vertraut sein. In diesem Artikel geben wir einen Überblick über häufig auftretende Pitfalls in der [¹⁸F]FDG PET/CT bei Lymphomen sowie über seltene Ursachen für Fehlbefunde und deren Interpretation.

Abstract

Malignant lymphoma is a quite common malignancy affecting all age groups. The usefulness of positron emission tomography/computed tomography using 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG PET/CT) has already been widely established in the assessment of Hodgkin lymphoma and many forms of non-Hodgkin lymphoma. However, many factors such as histopathological characteristics and previous and ongoing therapies may affect the [18F]FDG uptake in various organs. Furthermore, nuclear medicine physicians should be familiar with imaging variants and atypical findings as well as common pitfalls, which may cause misinterpretation and might lead to inappropriate management of the disease. In this article we review common pitfalls and variants of [18F]FDG PET/CT imaging in lymphoma and present cases with atypical findings with recommendations on accurate interpretation.

Schlüsselwörter

Lymphom - [¹⁸F]FDG, PET/CT - Pitfalls - onkologische Diagnostik

Keywords

lymphoma - [¹⁸F]FDG, PET/CT - pitfalls - oncological diagnostics

Full Text

References

Literatur
1 Barrington SF, OʼDoherty MJ. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging 2003; 30 (Suppl. 01) S117-127
2 Pauwels EK, Ribeiro MJ, Stoot JH. et al. FDG accumulation and tumor biology. Nucl Med Biol 1998; 25: 317-322
3 Barrington SF, Mikhaeel NG, Kostakoglu L. et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014; 32: 3048-3058
4 Cheson BD, Fisher RI, Barrington SF. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32: 3059-3068
5 Kubota R, Yamada S, Kubota K. et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33: 1972-1980
6 Parysow O, Mollerach AM, Jager V. et al. Low-dose oral propranolol could reduce brown adipose tissue F-18 FDG uptake in patients undergoing PET scans. Clin Nucl Med 2007; 32: 351-357
7 Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med 2009; 50 (Suppl. 01) 21s-30s
8 Barrington SF, Qian W, Somer EJ. et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010; 37: 1824-1833
9 Hoang-Xuan K, Bessell E, Bromberg J. et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol 2015; 16: e322-e332
10 Hojgaard L, Berthelsen AK, Loft A. Head and neck: normal variations and benign findings in FDG positron emission tomography/computed tomography imaging. PET Clin 2014; 9: 141-145
11 Nakamoto Y, Tatsumi M, Hammoud D. et al. Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology 2005; 234: 879-885
12 Bertagna F, Treglia G, Piccardo A. et al. Diagnostic and clinical significance of F-18-FDG-PET/CT thyroid incidentalomas. The Journal of clinical endocrinology and metabolism 2012; 97: 3866-3875
13 Seo YL, Yoon DY, Baek S. et al. Incidental focal FDG uptake in the parotid glands on PET/CT in patients with head and neck malignancy. Eur Radiol 2015; 25: 171-177
14 Ferdinand B, Gupta P, Kramer EL. Spectrum of thymic uptake at 18F-FDG PET. Radiographics 2004; 24: 1611-1616
15 Wachsmann JW, Gerbaudo VH. Thorax: normal and benign pathologic patterns in FDG-PET/CT imaging. PET Clin 2014; 9: 147-168
16 Alavi A, Gupta N, Alberini JL. et al. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med 2002; 32: 293-321
17 Heron CW, Husband JE, Williams MP. Hodgkin disease: CT of the thymus. Radiology 1988; 167: 647-651
18 Leibundgut K, Willi U, Pluss HJ. Thymic rebound following successful chemotherapy of B-lymphoma in an adolescent boy. Eur J Pediatr 1992; 151: 95-97
19 Michigishi T, Mizukami Y, Shuke N. et al. Visualization of the thymus with therapeutic doses of radioiodine in patients with thyroid cancer. Eur J Nucl Med 1993; 20: 75-79
20 Brink I, Reinhardt MJ, Hoegerle S. et al. Increased metabolic activity in the thymus gland studied with 18F-FDG PET: age dependency and frequency after chemotherapy. J Nucl Med 2001; 42: 591-595
21 Caffey J, Silbey R. Regrowth and overgrowth of the thymus after atrophy induced by the oral administration of adrenocorticosteroids to human infants. Pediatrics 1960; 26: 762-770
22 Paidisetty S, Blodgett TM. Brown fat: atypical locations and appearances encountered in PET/CT. AJR Am J Roentgenol 2009; 193: 359-366
23 Karam M, Roberts-Klein S, Shet N. et al. Bilateral hilar foci on 18F-FDG PET scan in patients without lung cancer: variables associated with benign and malignant etiology. J Nucl Med 2008; 49: 1429-1436
24 Ungprasert P, Carmona EM, Utz JP. et al. Epidemiology of Sarcoidosis 1946–2013: A Population-Based Study. Mayo Clin Proc 2016; 91: 183-188
25 Dubreuil J, Salles G, Bozzetto J. et al. Usual and unusual pitfalls of 18F-FDG-PET/CT in lymphoma after treatment: a pictorial review. Nucl Med Commun 2017; 38: 563-576
26 Takahashi H, Yamashita H, Morooka M. et al. The utility of FDG-PET/CT and other imaging techniques in the evaluation of IgG4-related disease. Joint Bone Spine 2014; 81: 331-336
27 Groves AM, Win T, Screaton NJ. et al. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET/CT. J Nucl Med 2009; 50: 538-545
28 Deandreis D, Leboulleux S, Dromain C. et al. Role of FDG PET/CT and chest CT in the follow-up of lung lesions treated with radiofrequency ablation. Radiology 2011; 258: 270-276
29 Zukotynski K, Kim CK. Abdomen: normal variations and benign conditions resulting in uptake on FDG-PET/CT. PET Clin 2014; 9: 169-183
30 Mahmud MH, Nordin AJ, Ahmad Saad FF. et al. Impacts of biological and procedural factors on semiquantification uptake value of liver in fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography imaging. Quantitative imaging in medicine and surgery 2015; 5: 700-707
31 Ghimire P, Wu GY, Zhu L. Primary gastrointestinal lymphoma. World J Gastroenterol 2011; 17: 697-707
32 Herrmann R, Panahon AM, Barcos MP. et al. Gastrointestinal involvement in non-Hodgkinʼs lymphoma. Cancer 1980; 46: 215-222
33 Gontier E, Fourme E, Wartski M. et al. High and typical 18F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging 2008; 35: 95-99
34 Boland GW, Lee MJ, Gazelle GS. et al. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol 1998; 171: 201-204
35 de Jong PA, van Ufford HM, Baarslag HJ. et al. CT and 18F-FDG PET for noninvasive detection of splenic involvement in patients with malignant lymphoma. AJR Am J Roentgenol 2009; 192: 745-753
36 Pilkington P, Lopci E, Adam JA. et al. FDG-PET/CT Variants and Pitfalls in Haematological Malignancies. Semin Nucl Med 2021; 51: 554-571
37 Khademi S, Westphalen AC, Webb EM. et al. Frequency and etiology of solitary hot spots in the pelvis at whole-body positron emission tomography/computed tomography imaging. Clin Imaging 2009; 33: 44-48
38 Kohan A, Avril NE. Pelvis: normal variants and benign findings in FDG-PET/CT imaging. PET Clin 2014; 9: 185-193
39 Lin KH, Chen YS, Hu G. et al. Chronic bacterial prostatitis detected by FDG PET/CT in a patient presented with fever of unknown origin. Clin Nucl Med 2010; 35: 894-895
40 Metser U, Even-Sapir E. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT. Semin Nucl Med 2007; 37: 206-222
41 Dammacco F, Rubini G, Ferrari C. et al. (1) (8)F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders. Clin Exp Med 2015; 15: 1-18
42 Choi YY, Kim JY, Yang SO. PET/CT in benign and malignant musculoskeletal tumors and tumor-like conditions. Semin Musculoskelet Radiol 2014; 18: 133-148
43 Błaż M, Palczewski P, Swiątkowski J. et al. Cortical fibrous defects and non-ossifying fibromas in children and young adults: The analysis of radiological features in 28 cases and a review of literature. Polish journal of radiology 2011; 76: 32-39
44 Pagano M, Berta M, Postini AM. et al. Nonossifying fibroma: A possible pitfall in F18-FD-PET/CT imaging of Hodgkinʼs disease. Radiol Case Rep 2011; 6: 271
45 Rahman WT, Wale DJ, Viglianti BL. et al. The impact of infection and inflammation in oncologic (18)F-FDG PET/CT imaging. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2019; 117: 109168
46 Thomas DL, Syrbu S, Graham MM. Epstein-Barr virus mimicking lymphoma on FDG-PET/CT. Clin Nucl Med 2009; 34: 891-893
47 Pan Q, Luo Y, Wu H. et al. Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis Mimicking Lymphoma on FDG PET/CT. Clin Nucl Med 2018; 43: 125-127
48 Ørbæk M, Graff J, Markova E. et al. (18)F-FDG PET/CT Findings in Acute Epstein-Barr Virus Infection Mimicking Malignant Lymphoma. Diagnostics (Basel, Switzerland) 2016; 6: 18
49 Lustberg MB, Aras O, Meisenberg BR. FDG PET/CT findings in acute adult mononucleosis mimicking malignant lymphoma. European journal of haematology 2008; 81: 154-156
50 Makis W, Hickeson M, Blumenkrantz M. Interesting image. Dermatopathic lymphadenitis: a pitfall for lymphoma evaluation by F-18 FDG PET/CT. Clin Nucl Med 2010; 35: 872-874
51 Graveleau J, Grossi O, Lefebvre M. et al. Vertebral osteomyelitis: an unusual presentation of Bartonella henselae infection. Seminars in arthritis and rheumatism 2011; 41: 511-516
52 Makis W, Ciarallo A, Gonzalez-Verdecia M. et al. Systemic Lupus Erythematosus Associated Pitfalls on (18)F-FDG PET/CT: Reactive Follicular Hyperplasia, Kikuchi-Fujimoto Disease, Inflammation and Lymphoid Hyperplasia of the Spleen Mimicking Lymphoma. Nucl Med Mol Imag 2018; 52: 74-79
53 Geerdes-Fenge HF, Löbermann M, Warnke P. et al. Mediastinal Lymphadenopathy – Tuberculosis or Tularemia?. Dtsch Med Wochenschr (1946) 2019; 144: 1276-1279
54 Martinet P, Khatchatourian L, Saidani N. et al. Hypermetabolic pulmonary lesions on FDG-PET/CT: Tularemia or neoplasia?. Infect Dis Now 2021; 51: 607-613
55 Mortensen BK, Nielsen SD, Christensen CB. et al. Immune reconstitution syndrome presenting as probable AIDS-related lymphoma: a case report. AIDS Res Ther 2011; 8: 34
56 Sohn S, Shi HJ, Wang SH. et al. Mycobacterium avium complex infection-related immune reconstitution inflammatory syndrome mimicking lymphoma in an human immunodeficiency virus-infected patient. Infect Chemother 2018; 50: 350-356
57 Schwerz S, Mueller M, Lindemann-Docter K. et al. Hepatic candidiasis mimicking lymphoma on 18F-FDG PET/CT in a patient with T cell lymphoma. Eur J Nuclear Med Mol Imag 2020; 47: 2925-2926
58 Egeler RM, Neglia JP, Aricò M. et al. Acute leukemia in association with Langerhans cell histiocytosis. Med Pediat Oncol 1994; 23: 81-85
59 Ben-Haim S, Ell P. 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med 2009; 50: 88-99
60 Nilak YD, Nilak A, Shafeek S. et al. Benign histiocyte-rich pseudotumor in post treatment mediastinal Hodgkinʼs lymphoma. Radiology case reports 2020; 15: 156-60
61 Mainolfi CG, DʼAntonio A, Mango G. et al. Ileal inflammatory pseudotumor in adolescent male patient with prior Burkitt lymphoma: A challenging diagnosis. Radiol Case Rep 2021; 16: 2047-2052
62 Hod N, Lantsberg S, Anconina R. et al. Postchemotherapy Histiocyte-Rich Pseudotumor of the Spleen Simulating Residual Disease in a Patient With Non-Hodgkin Lymphoma on FDG PET/CT. Clin Nucl Med 2019; 44: e409-e412
63 Kashyap R, Lau E, George A. et al. High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma. European journal of nuclear medicine and molecular imaging 2013; 40: 1330-1336
64 Belakhlef A, Jani C, Church C. et al. Fat necrosis mimicking B-cell lymphoma: a PET/CT and FDG study. Clin Nucl Med 2008; 33: 271-272
65 Kapoor H, Hatfield W, El Khouli R. et al. Iatrogenic Cushingʼs syndrome on (18)F-FDG-PET/CT: A pitfall in metabolic assessment of oncologic response. Clin Imag 2021; 75: 27-29
66 Hofman MS, Hicks RJ. White fat, factitious hyperglycemia, and the role of FDG PET to enhance understanding of adipocyte metabolism. EJNMMI research 2011; 1: 2
67 Kong MC, Nadel HR. 18F-FDG PET/CT With Diffusely High FDG Uptake Throughout Subcutaneous Adipose Tissues. Clin Nucl Med 2018; 43: 762-763
68 OO JH, Lodge MA, Wahl RL. Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. Radiology 2016; 280: 576-584
69 Bleeker-Rovers CP, van der Ven AJ, Zomer B. et al. F-18-fluorodeoxyglucose positron emission tomography for visualization of lipodystrophy in HIV-infected patients. AIDS 2004; 18: 2430-2432
70 Niu N, Zhu ZH, Ma YR. et al. Features of Acquired Immunodeficiency Syndrome-related Lymphoma on (18)F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. Zhongguo yi xue ke xue yuan xue bao Acta Academiae Medicinae Sinicae 2015; 37: 602-606
71 Caton Jr MT, Miskin N, Hyun H. 18F-FDG Uptake in subcutaneous fat preceding clinical diagnosis of human immunodeficiency virus-associated lipodystrophy. Clin Nucl Med 2018; 43: e475-e476
72 Thomassen A, Lerberg Nielsen A, Gerke O. et al. Duration of 18F-FDG avidity in lymph nodes after pandemic H1N1v and seasonal influenza vaccination. Eur J Nucl Med Mol Imaging 2011; 38: 894-898
73 Shin M, Hyun CY, Choi YH. et al. COVID-19 Vaccination-Associated Lymphadenopathy on FDG PET/CT: Distinctive Features in Adenovirus-Vectored Vaccine. Clin Nucl Med 2021; 46: 814-819
74 Mingos M, Howard S, Giacalone N. et al. Systemic Immune Response to Vaccination on FDG-PET/CT. Nucl Med Mol Imag 2016; 50: 358-361
75 Ayati N, Jesudason S, Berlangieri SU. et al. Generalized Lymph Node Activation after Influenza Vaccination on (18)F FDG-PET/CT Imaging, an Important Pitfall in PET Interpretation. Asia Ocean J Nucl Med Biol 2017; 5: 148-150
76 Bacanovic S, Stiller R, Pircher M. et al. Ovarian Hyperstimulation and Oocyte Harvesting Prior to Systemic Chemotherapy-A Possible Pitfall in 18F-FDG PET/CT Staging of Oncologic Patients. Clin Nucl Med 2016; 41: e394-e396
77 Cunningham 3rd JR, OʼMalley JP. et al. Ovarian hyperstimulation and breast cancer on PET imaging with sonographic correlation. Clin Nucl Med 2015; 40: 430-432
78 Subhas N, Patel PV, Pannu HK. et al. Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. Radiographics 2005; 25: 1031-1043